FDA offers former biotech unicorn Intarcia a chance for a panel review

FDA offers former biotech unicorn Intarcia a chance for a panel review

Source: 
BioPharma Dive
snippet: 

The Food and Drug Administration will permit Intarcia Therapeutics to request a public advisory committee hearing for its diabetes drug-eluting implant following two previous rejections over its kidney and heart risks.